Webinar and Panel Discussion: New data on how ctDNA is evolving oncology patient management and drug development

In the Driver's Seat with Signatera

How can real-world clinicogenomics data accelerate drug development?

Build early evidence that your investigational drug is working

Monitoring immunotherapy treatment response with ctDNA Real-world applications of Signatera in melanoma

See how Beth worked with her doctor to use Signatera to help guide her cancer treatment plan

2.11 Webinar (slides and video) (circulate japan LP)

SignaCase: Treatment response monitoring in Stage IV EGFR+ NSCLC

Signatera is a personalized tumor-informed test that can help doctors detect cancer progression earlier. Learn how Signatera helped JoAnn and her family stay confident and positive throughout her lung

Real-world clinical applications of Signatera in IO monitoring

Real-world clinical applications of Signatera in IO monitoring direct

2.11 Webinar (slides and video)

Using ctDNA to guide the management of GI cancers

Latest Data in Breast Cancer Response Monitoring and Relapse Prediction

Jeff’s Story: See how Signatera “takes away the question marks” to help take control of cancer

SignaCase: A Case Review: Long-term stable disease on immunotherapy

Innovations in Clinical Trial Design with ctDNA MRD

When CEA tells us very little

Signatera for immunotherapy response monitoring- Spanish version

Signatera is a personalized blood test, designed to track mutations specific to each patient's tumor. Your doctor can use Signatera alongside imaging tests to better assess your response to immunother

The use of ctDNA assays to inform shared decision-making

Natera 02 - Short Version